2 weeks Ago By ABMN Staff
ProQR Therapeutics ( NASDAQ:PRQR – Free Report ) – Equities researchers at Chardan Capital reduced their FY2024 earnings estimates for shares of ProQR Therapeutics in a research report issued on Sunday, November 10th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings per share of ($0.
31) for the year, down from their previous estimate of ($0.28). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.
34) per share. Chardan Capital also issued estimates for ProQR Therapeutics’ FY2025 earnings at ($0.34) EPS.
A number of other research analysts have also recently commented on the company. HC Wainwright raised their target price on ProQR Therapeutics from $5.00 to $10.
00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $6.00 to $14.
00 in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.
13. ProQR Therapeutics Stock Performance ProQR Therapeutics stock opened at $3.95 on Wednesday.
ProQR Therapeutics has a fifty-two week low of $1.18 and a fifty-two week high of $4.62.
The stock’s 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $2.15.
The stock has a market cap of $322.64 million, a price-to-earnings ratio of -12.34 and a beta of 0.
26. Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in shares of ProQR Therapeutics in the first quarter worth $56,000.
BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 19,100 shares in the last quarter.
EP Wealth Advisors LLC purchased a new position in ProQR Therapeutics in the first quarter worth about $26,000. Ikarian Capital LLC lifted its stake in shares of ProQR Therapeutics by 2.3% in the first quarter.
Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after buying an additional 10,958 shares in the last quarter. Finally, Privium Fund Management B.V.
grew its holdings in shares of ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.
V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after buying an additional 236,279 shares during the last quarter. Institutional investors own 32.
65% of the company’s stock. ProQR Therapeutics Company Profile ( Get Free Report ) ProQR Therapeutics N.V.
, a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). Further Reading Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
